WeTrials
Recruiting

A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

What is this study?

This study is testing a new combination of precise radiation and two immunotherapy drugs to see if they can help the immune system fight pancreatic cancer that has spread. Researchers hope this approach will offer a helpful new option for patients when standard treatments have stopped working.

Who can participate?

You may be able to join if you are 18 or older, have pancreatic cancer that has spread to other parts of the body, and have tried at least one prior treatment. There are some health and history conditions, such as certain liver tumor sizes or active immune disorders, that mean this study might not be the right fit.

What will happen?

Participants will receive targeted radiation therapy directly to the tumor, followed by two immunotherapy medications called botensilimab and balstilimab. Your health care team will monitor you closely throughout the process to see how your body responds to the treatment.

Where and when?

This study is currently recruiting participants and takes place in Miami, Florida. Your study team can provide all the details about scheduling and visits.

Key Points
  • 1Combines targeted radiation with two immunotherapy medicines
  • 2Designed for adults with advanced pancreatic cancer who need new options
  • 3Currently active and recruiting patients in Miami, Florida

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.